AI cuts drug development time, cost by targeting formulation early

Drug development has long been constrained by time, cost, and high failure rates—only about 10% of candidates make it through clinical development—creating pressure for tools that can de-risk early decisions. Traditional empirical approaches, while still essential, require iterative cycles that consume both time and expensive active pharmaceutical ingredients (API) without guaranteeing success. AI predictive modelling addresses this by analysing molecular data to identify viable formulations before costly experiments, thereby shifting decision-making to the earliest, highest-uncertainty stages where the downstream impact is greatest.

The regulatory environment has moved in parallel. The joint guidance from the EMA and FDA in January 2026 signals that regulators now expect AI integration to follow rigorous, transparent, and validated practices—not a free-for-all. This framing (detailed record-keeping, risk assessment, experimental validation) emphasises that AI outputs are a starting point for human review, not a replacement for it, and that confidence comes from traceability and evidence, not speed alone. In contexts like oncology, central nervous system disorders, immunology, and infectious diseases, where molecular complexity is high, AI's ability to navigate that complexity early could yield meaningful cost and timeline savings. However, realising these benefits depends on companies combining AI predictions with targeted experimental validation and maintaining the documentation standards regulators now expect.